Artal Group S.A.

In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 14, 2025), Artal Group S.A. reported 2 stock positions worth $1.2 billion. Its top holding was Cava (CAVA) at 91.4% of the portfolio, followed by Lexicon Pharmaceuticals (LXRX, 8.6%). Compared with Q3 2024, it reduced 1. The biggest sale was Cava (CAVA, shares −46%).

Most Recent 13F
Q2 2026
Location
LUXEMBOURG, N4
CIK
0001053906
Portfolio Value
$1.2B (Q4 2024)
SEC Filing
0001053906-25-000002 ↗ filed Feb 14, 2025

Holdings Value

0$1.0B$2.0B$3.0B$4.0B Q1 2024: $3.9B Q1 2024 Q2 2024: $3.9B Q2 2024 Q3 2024: $2.4B Q3 2024 Q4 2024: $1.2B $1.2B Q4 2024 Q1 2025: $884.2M Q1 2025 Q2 2025: $930.2M Q2 2025 Q3 2025: $758.2M Q3 2025 Q4 2025: $714.6M Q4 2025 Q1 2026: $1.0B Q1 2026 Q2 2026: $931.1M Q2 2026

Holdings 2 stocks · $1.2B
CAVA Cava Group Inc. 91.41% 9,507,990 $1.1B Reduce -45.7%
LXRX Lexicon Pharmaceuticals Inc. 8.59% 136,180,481 $100.8M No change

Portfolio Sells Q3 2024 → Q4 2024
CAVA Cava Group Inc. Reduce -45.7% 91.41% +0.39

Portfolio Buys Q3 2024 → Q4 2024
None this quarter.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 2$931.1MCAVA, LXRX
Q1 2026 2$1.0BCAVA, LXRX
Q4 2025 2$714.6MCAVA, LXRX
Q3 2025 2$758.2MCAVA, LXRX
Q2 2025 2$930.2MCAVA, LXRX
Q1 2025 2$884.2MCAVA, LXRX
Q4 2024 2$1.2BCAVA, LXRX
Q3 2024 2$2.4BCAVA, LXRX
Q2 2024 108$3.9BCAVA, LXRX, SRRK, KYMR, MORF
Q1 2024Amended 107$3.9BCAVA, LXRX, SRRK, KYMR, ARWR